Abstract:1. CCNB1IP1 was overexpressed in MYCN‐amplified NB and was associated with poor prognosis. 2. CCNB1IP1 facilitated MYCN‐driven proliferation and tumourigenesis of NB cells. 3. MYCN directly activated CCNB1IP1 transcription, which in turn stabilized MYCN by competing with FBXW7 for MYCN binding in a C‐terminal domain‐dependent manner. Background MYCN amplification as a common genetic alteration that correlates with a poor prognosis for neuroblastoma (NB) patients. However, given the challenge of directly targeting MYCN, indirect strategies to modulate MYCN by interfering with its cofactors are attractive in NB treatment. Although cyclin B1 interacting protein 1 (CCNB1IP1) has been found to be upregulated in MYCN‐driven mouse NB tissues, its regulation with MYCN and collaboration in driving the biological behaviour of NB remains unknown. Methods To evaluate the expression and clinical significance of CCNB1IP1 in NB patients, public datasets, clinical NB samples and cell lines were explored. MTT, EdU incorporation, colony and tumour sphere formation assays, and a mouse xenograft tumour model were utilized to examine the biological function of CCNB1IP1. The reciprocal manipulation of CCNB1IP1 and MYCN and the underlying mechanisms involved were investigated by gain‐ and loss‐of‐function approaches, dual‐luciferase assay, chromatin immunoprecipitation (CHIP) and co‐immunoprecipitation (Co‐IP) experiments. Results CCNB1IP1 was upregulated in MYCN‐amplified (MYCN‐AM) NB cell lines and patients‐derived tumour tissues, which was associated with poor prognosis. Phenotypic studies revealed that CCNB1IP1 facilitated the proliferation and tumourigenicity of NB cells in cooperation with MYCN in vitro and in vivo. Mechanistically, MYCN directly mediates the transcription of CCNB1IP1, which in turn attenuated the ubiquitination and degradation of MYCN protein, thus enhancing CCNB1IP1‐MYCN cooperativity. Moreover, CCNB1IP1 competed with F box/WD‐40 domain protein 7 (FBXW7) for MYCN binding and enabled MYCN‐mediated tumourigenesis in a C‐terminal domain‐dependent manner. Conclusions Our study revealed a previously uncharacterized mechanism of CCNB1IP1‐mediated MYCN protein stability and will provide new prospects for precise treatment of MYCN‐AM NB based on MYCN‐CCNB1IP1 interaction.

N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 ( NLRR1 ) gene in neuroblastoma

Data from NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i>

Nlrr1 Enhances Egf-Mediated Mycn Induction In Neuroblastoma And Accelerates Tumor Growth In Vivo

NLRR1 is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers

MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and is Activated Through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification.

Myc Activation Through Enhancer Hijacking Or Focal Enhancer Amplification Drives A Subset Of High-Risk Pediatric Neuroblastoma

The Long Noncoding RNA Lncnb1 Promotes Tumorigenesis by Interacting with Ribosomal Protein RPL35

Abstract C15: Combinatorial Regulation of Neuroblastoma Tumor Progression by HIF1α and N-myc Transcriptional Factors

A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle

Genetic Clinical Markers of Human Neuroblastoma with Special Reference to N-<i>myc</i> Oncogene: Amplified or Not Amplified? &ndash; an Overview

Data from Combinatorial Regulation of Neuroblastoma Tumor Progression by N-Myc and Hypoxia Inducible Factor HIF-1α

CCNB1IP1 prevents ubiquitination-mediated destabilization of MYCN and potentiates tumourigenesis of <i>MYCN</i>-amplificated neuroblastoma

Supplementary Figure 4 from NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i>

Decreased Expression of N-myc Protein Inhibits Cell Proliferation and Migration of Neuroblastoma Cell Line SK-N-BE (2)

LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis.

Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma

Wdr5 Supports An N-Myc Transcriptional Complex That Drives A Protumorigenic Gene Expression Signature In Neuroblastoma

CCNB1IP1 stabilizes MYCN through suppression of Fbxw7-mediated degradation and facilitates the growth of MYCN-amplified neuroblastoma

CCNB1IP1 prevents ubiquitination‐mediated destabilization of MYCN and potentiates tumourigenesis of MYCN‐amplificated neuroblastoma

Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma